医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LEO Pharma initiates phase 2b clinical studies of topical delgocitinib cream in adults for the treatment of both atopic dermatitis and chronic hand eczema

2018年12月03日 PM03:00
このエントリーをはてなブックマークに追加


 

BALLERUP, Denmark

LEO Pharma A/S, a global leader in medical dermatology, announces today that it has enrolled the first patients in two new phase 2b clinical studies to investigate delgocitinib, a novel topical pan-Janus kinase inhibitor (JAKi), as a monotherapy for adults with mild-to-severe atopic dermatitis (AD) as well as mild-to-severe chronic hand eczema (CHE).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181202005029/en/

Both phase 2b trials are double-blind, randomized, vehicle-controlled, dose-ranging trials to evaluate the efficacy and safety of twice-daily topical application of delgocitinib cream. Both investigator- and patient-assessed outcomes will be measured in the clinical trials.

“Atopic dermatitis and chronic hand eczema are highly symptomatic and can have a profoundly negative impact on the lives of the people who suffer from them. There are still many unmet therapeutic needs for both disorders, including a need for new, highly efficacious treatments with fewer side effects,” said Jonathan Silverberg, MD, PhD, Associate Professor of Dermatology at Northwestern University Feinberg School of Medicine, Chicago, Illinois, and lead investigator in the AD trial. “Delgocitinib has a novel mechanism of action and the potential to offer both excellent efficacy and safety in atopic dermatitis and chronic hand eczema.”

Further information about trials with topical delgocitinib cream can be accessed via https://clinicaltrials.gov

View source version on businesswire.com: https://www.businesswire.com/news/home/20181202005029/en/

CONTACT

Media
Head of Global External
Communication
Henrik Steen Heskjaer Kyndlev
hdtdk@leo-pharma.com
TEL
+45 7226 3399

Global Product Communications, Eczema
Kimberly Whitefield
kqwus@leo-pharma.com
TEL
+1 862 345 0643

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity
  • Aptorum Group Limited Announces Pricing of Initial Public Offering
  • Seattle Genetics和武田呈报 ADCETRIS® (Brentuximab Vedotin)用于表达CD30的外周T细胞淋巴瘤一线治疗3期ECHELON-2临床试验的阳性数据
  • 武田の株主がシャイアー買収案に関連した決議事項を承認
  • 武田股东批准拟收购Shire plc相关决议